- Home
- CCEC vs ABCL Comparison
CCEC vs ABCL Comparison
Compare CCEC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCEC | ABCL |
|---|---|---|
| Price | $20.78 | $3.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $25.50 | $7.75 |
| AVG Volume (30 Days) | 4.9K | ★ 4.9M |
| Earning Date | 02-06-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $421,795,000.00 | $35,325,000.00 |
| Revenue This Year | $14.29 | $25.45 |
| Revenue Next Year | $12.32 | $10.07 |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | ★ 32.74 | 7.17 |
| 52 Week Low | $14.09 | $1.89 |
| 52 Week High | $24.83 | $6.52 |
Technical Indicators
Market Signals| Indicator | CCEC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 37.27 |
| Support Level | $20.21 | $2.75 |
| Resistance Level | $22.58 | $3.28 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 23.84 | 19.48 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.